Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months.
D000293:Adolescent; D000328:Adult; D000906:Antibodies; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D012293:Rifampin / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D012846:Singapore; D013921:Thrombocytopenia / Q000139:chemically induced; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000906:Antibodies; D007538:Isoniazid; D012293:Rifampin